Research never stops

PsychoGenics Inc.

PsychoGenics, based in Tarrytown, New York, is a leader in pre-clinical behavioural neurobiology. The Company applies its behavioural expertise together with advances in robotics, computer vision and informatics to provide innovative solutions for CNS drug discovery. PsychoGenics works with pharmaceutical and biotechnology companies, academic institutions, and not-for-profit research foundations to help discover treatments for such major neurological and psychiatric disorders as: ALS, anxiety, cognitive impairment, depression, Huntington's Disease, psychosis/schizophrenia, and Spinal Muscular Atrophy (SMA). PsychoGenics has ongoing relationships with Roche, Lilly, CHDI, SMA Foundation and others. For more information about PsychoGenics please visit www.psychogenics.com.

The strategic alliance of Evotec and PsychoGenics makes it possible to provide integrated CNS drug discovery solutions to pharmaceutical and biotech companies. Access to complementary drug discovery platforms for the identification and development of new therapeutics to treat CNS disorders can be provided to already existing and new clients. Furthermore, due to the cooperation, pre-clinical candidates can be delivered in the most time and cost-efficient manner, fully-integrated and proprietary capabilities can be availed to drive and transform CNS discovery programmes.